Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Mobia Medical, Inc. is a commercial-stage medical device company focused on redefining stroke recovery for survivors with moderate to severe upper extremity motor impairments. Its flagship product, the Vivistim Paired VNS System, is the first and only FDA-approved implantable solution that pairs targeted vagus nerve stimulation with functional movement exercises to promote neuroplasticity and enhance upper limb function in chronic ischemic stroke patients. This innovative therapy addresses a critical gap in post-stroke rehabilitation by driving meaningful, lasting improvements in motor recovery. Mobia Medical, Inc. supports patients, healthcare providers, and care partners through its commercial operations, emphasizing accessible stroke care solutions. The company operates within the neurostimulation and rehabilitation medical device sector, targeting the needs of chronic stroke survivors. Founded in 2007 and headquartered in Austin, Texas, Mobia Medical, Inc. plays a pivotal role in advancing therapeutic options for neurological recovery in the medical technology market.
$12.58
$0.15 (-1.18%)
EOD Aug 11, 2026
The business is unprofitable at the operating level (-144.71% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 104.8% YoY with margins expanding 10.2pp.
ROIC dropped from -247.99% to -453.46%, capital efficiency is deteriorating. Negative free cash flow of -$46M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$32M
▲ +104.8% YoY
Net Income (TTM)
-$46M
▼ -89.0% YoY
Op. Margin
-144.71%
▲ +10.2pp YoY
ROIC
-453.46%
▼ -205.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$46M
▼ -89.1% YoY
Op. Cash Flow (TTM)
-$46M
▼ -87.9% YoY
Net Debt
-$25M
Net Cash Position
Cash & Equiv.
$34M
Continue Research
Mobia Medical (MOBI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Mobia Medical scores 48/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Mobia Medical scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -144.7% operating margin and a -453.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MOBI's valuation and scores 48/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.